ClinicalTrials.gg
CompletedNCT05110196Updated Oct 26, 2026Results posted

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

A Phase 4 interventional study of Capmatinib 150 mg and Capmatinib 200 mg in Non-Small Cell Lung Carcinoma, sponsored by Novartis Pharmaceuticals. Completed at 15 sites in India. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

How we know

Updated Oct 26, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing capmatinib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 3 under way, none of them phase 3. capmatinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
9th of 21
50 · median 35
Started
2022
with 3 others
Phase 4
Only one
of the 21
Registered
17th of 21
by date
Lead sponsor
16 of 21
Novartis Pharmaceuticals

Among the 21 studies testing capmatinib in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by enrollment, is one of 4 that started in 2022, is the only one in phase 4, and was the 17th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 21 studies testing capmatinib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About capmatinib

capmatinib: first FDA approval 2020 (TABRECTA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing capmatinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The Drugs Controller General of India (DCGI) granted approval for Rahika® (capmatinib) film-coated tablets (150 mg and 200 mg) for the treatment of adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbored a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping. As a condition of approval, the DCGI required the conduct of a Phase IV clinical trial in Indian patients. As recommended by the DCGI, this Phase IV study was planned to evaluate the safety and efficacy of capmatinib in adult Indian patients with advanced or metastatic NSCLC with MET exon 14 skipping mutation-positive disease, in any line of therapy.

Read the detailed description

This was a Phase IV, prospective, multicenter, open-label, interventional study evaluating the safety and efficacy of capmatinib in Indian patients with metastatic non-small cell lung cancer (NSCLC) harboring a MET exon 14 skipping mutation, in any line of therapy. A total of 50 patients were included, with an overall study duration of approximately 2.5 years.

The study consisted of a molecular pre-screening phase of up to 28 days for patients without documented MET exon 14 skipping mutation-positive status, followed by a screening period of up to 28 days, a treatment period of 24 weeks (6 months), an end-of-treatment (EOT) visit, and a follow-up period of 30 days after the last dose of study treatment. Molecular testing was performed centrally using a next-generation sequencing (NGS)-based platform on formalin-fixed, paraffin-embedded (FFPE) tumor samples. Patients with confirmed MET exon 14 skipping mutation, epidermal growth factor receptor (EGFR) wild-type status, and anaplastic lymphoma kinase (ALK)-negative status were eligible for enrollment. Patients negative for MET exon 14 skipping mutation or positive for other biomarkers were excluded and treated according to standard of care.

All eligible participants received capmatinib as the investigational therapy. Capmatinib film-coated tablets (strengths of 150 mg and 200 mg) were administered orally at a starting dose of 400 mg twice daily (BID) on a continuous dosing schedule. Treatment was initiated only after prior anticancer therapy, if applicable, had been discontinued for at least 4 weeks or for a minimum of five times the drug half-life, whichever was longer. The treatment period began on Day 1 of Cycle 1, with each treatment cycle defined as 21 days. Cycle 2 began on Day 22 (Cycle 2 Day 22 [C2D22]), and subsequent cycles followed accordingly in the absence of temporary treatment discontinuation. Dose interruptions and dose reductions to 300 mg BID and subsequently 200 mg BID were permitted per protocol-defined criteria based on patient tolerability. Tablets were administered with or without food and were swallowed whole without chewing, crushing, or breaking.

Treatment was planned for a duration of 24 weeks and continued until disease progression, unacceptable toxicity, withdrawal of consent, or death, or at the discretion of the investigator or the patient. Efficacy assessments were performed every 6 weeks (±7 days) from Cycle 1 Day 1 until disease progression, with radiological assessments conducted using consistent imaging modalities throughout the study. Safety assessments included monitoring of adverse events, laboratory parameters, electrocardiograms (ECGs), and concomitant medications, and patients maintained subject diaries to assess treatment compliance.

Patients who discontinued treatment prematurely underwent end-of-study (EOS) assessments 30 days after administration of the last dose of study treatment. Patients who discontinued treatment without documented disease progression were followed for disease progression until EOS. Completion of the 30-day follow-up period marked EOS.

Post-trial access (PTA) to capmatinib was provided by Novartis to patients who were ongoing on treatment at the end of the planned study duration and were deriving clinical benefit, to ensure uninterrupted therapy beyond the study period. Patients transitioning to PTA were also required to complete the EOS visit assessments after the last dose of capmatinib administered within the study.

03

Conditions studied

  • Non-Small Cell Lung Carcinoma

Keywords

  • Carcinoma, Non-Small Cell Lung
  • Non-Small Cell Lung Cancer
  • Non small Cell Lung Cancer
  • Lung Neoplasms
  • Bronchial neoplasms
  • Mesenchymal-Epithelial Transition exon 14 Skipping Mutation Positive Advanced Non-Small Cell Lung Cancer
  • NSCLC
  • MET
  • Lung Cancer
  • Carcinoma
04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed must be obtained prior to participation in the study.
  2. Adult ≥18 years old at the time of informed consent.
  3. NSCLC (Stage IV, according to Version 8 of the AJCC Staging Manual) either treatment naïve or progressed (clinically and/or radiologically) on 1 or more .
  4. or cytologically confirmed diagnosis of NSCLC with confirmed EGFR wild type (EGFR Negative) and ALK rearrangement negative and who have tested positive MET exon14 skipping mutation (Locally available MET report either by reverse transcriptase polymerase chain reaction [RT-PCR] or NGS would be considered, in case not available, MET testing would be done through NGS based molecular pre-screening done as part of the study).
  5. Patients must have recovered from all toxicities related to prior systemic therapies to grade ≤1 ( [CTCAE] version 5.0).
  6. At least one as defined by 1.1.
  7. Patients must have adequate organ function, including the following laboratory values at the screening visit:

    1. ≥1.5 x 109/L without growth factor support
    2. ≥100 x 109/L
    3. ≥9 g/dL
    4. Calculated (using Cockcroft-Gault formula) ≥45 mL/min
    5. Total ≤1.5 (upper limit of normal) (except in patients with Gilbert's syndrome, who may be included if total bilirubin is ≤3.0 x ULN and direct bilirubin is ≤1.5 x ULN))
    6. ≤3 x ULN, except for patients with liver metastasis, who may only be included if AST ≤5 x ULN
    7. ALT ≤3 x ULN, except for patients with liver metastasis, who may only be included if ALT ≤5 x ULN
    8. Alkaline phosphatase (ALP) ≤5.0 x ULN
    9. Asymptomatic serum amylase ≤ grade 2. Patients with grade 1 or grade 2 serum amylase at the beginning of the study must be confirmed to have no signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.)
    10. Serum lipase ≤ ULN
  8. (ECOG) performance status (PS) of 0 to 2.
  9. Willing and able to comply with scheduled visits, treatment plan, and laboratory tests.

Exclusion criteria

Exclusion criteria

  1. Prior treatment with any MET inhibitor or hepatocyte growth factor targeting therapy.
  2. Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years. Exceptions to this exclusion include the following: completely resected basal cell and squamous cell skin cancers and completely resected carcinoma in situ of any type.
  3. Patients with symptomatic central nervous system (CNS) who are neurologically unstable or have required increasing doses of within the 2 weeks prior to study entry to manage CNS symptoms.
  4. Patients with known druggable molecular alterations (such as ROS1 translocation or BRAF mutation, etc.) which might be a candidate for alternative targeted therapies as applicable per local regulations and treatment guidelines.
  5. Presence or history of interstitial lung disease or interstitial pneumonitis, including radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention).
  6. Patient with clinically significant heart diseases like unstable angina/acute myocardial infraction within 6 months prior to screening, class III-IV congestive cardiac failure, uncontrolled hypertension, arrhythmias or ≥470 ms on the screening .
  7. Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior (2 weeks for resection of ) to starting Capmatinib or who have not recovered from side effects of such procedure. Video-assisted thoracic surgery and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the program ≥1 week after the procedure.
  8. Thoracic radiotherapy to lung fields ≤4 weeks prior to starting Capmatinib or patients who have not recovered from radiotherapy-related toxicities. For all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy ≤2 weeks prior to starting Capmatinib or patients who have not recovered from radiotherapy-related toxicities. Palliative radiotherapy for bone lesions ≤2 weeks prior to starting Capmatinib is allowed.
  9. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Capmatinib or patients who are unable to swallow oral tablets.
  10. Patients receiving treatment with strong inducers of that cannot be discontinued at least 1 week prior to the start of treatment with Capmatinib and for the duration of the study.
  11. Unable or unwilling to swallow tablets as per dosing schedule.
  12. Patients with known to Capmatinib and any of the of Capmatinib.
  13. Patients with any other severe, acute or chronic medical or psychotic conditions or significant abnormal physical findings that in the opinion of the investigator may increase the risk associated with study participation or that may interfere with the interpretation of study results.
  14. Patients with prior systemic anti-cancer (chemotherapy, immunotherapy, biologic therapy, vaccine) and agents within 4 weeks or ≤5 x half-life of the agent (whichever is shorter) before the first dose of Capmatinib. If previous treatment is a monoclonal antibody, then the treatment must be discontinued at least 4 weeks before first dose of Capmatinib. If previous treatment is an oral targeted agent, then the treatment must be discontinued at least 5 times the half-life of the agent.
  15. Pregnant or nursing (lactating) women.
  16. Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of while taking study treatment and for 7 days after stopping study treatment. Highly effective contraception methods include:

    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment.
    3. Male sterilization (at least 6 months prior to screening). For female patients on the study, the vasectomized male partner should be the sole partner for that patient.
    4. Use of oral (estrogen and progesterone), injected, or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking treatment.
  17. Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 7 days after stopping study treatment. A condom is required for all sexually active male patients to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, male patients must not donate sperm for the time period specified above.
  18. Any other condition that would, in the Investigator's judgment, contraindicate patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., active infection (including active and C, SARS-CoV-2), inflammation, intestinal obstruction, unable to swallow medication, social/psychological issues, etc
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Capmatinib

    Capmatinib (Rahika®) film-coated tablet administered as 400 mg orally twice daily on a continuous dosing schedule for 24 weeks.

    Drug: Capmatinib 150 mg · Drug: Capmatinib 200 mg

Interventions

  • DrugCapmatinibStudies of CapmatinibCapmatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Capmatinib film-coated tablet 150 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.

    Also known as: Rahika® 150mg

  • DrugCapmatinibStudies of CapmatinibCapmatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Capmatinib film-coated tablet 200 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.

    Also known as: Rahika® 200 mg

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events (Serious TEAEs)

    Treatment-emergent adverse events (TEAEs) were adverse events that occurred or worsened following initiation of study treatment and up to 30 days after the last dose of the study drug. Serious treatment-emergent adverse events (serious TEAEs) were TEAEs that met the criteria for a serious adverse event, defined as any adverse event that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was an abnormal pregnancy outcome.

    Time frame: From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months

  2. Percentage of Participants With Dose Modifications

    Percentage of participants experiencing dose modifications, including dose interruptions and dose reductions. Dose modifications were implemented to manage intolerance to the protocol-specified regimen and were based on the worst preceding toxicity graded according to NCI-CTCAE v5.0. Capmatinib dose reductions followed predefined dose levels (400 mg BID → 300 mg BID → 200 mg BID), with a maximum of two consecutive reductions and no reductions below 200 mg BID. Treatment was discontinued if clinically significant toxicity recurred at the lowest dose despite maximal supportive measures, or if treatment interruption exceeded 21 consecutive days, unless continuation was approved by the Novartis Medical Lead or designee. Dose re-escalation was permitted once after at least one treatment cycle (3 weeks) at the reduced dose, provided no dose-modifying adverse event occurred.

    Time frame: From first dose of study treatment administration until end of treatment, assessed up to approximately 6 months

  3. Dose Intensity

    Dose intensity was defined as the ratio of actual cumulative dose received to the actual duration of exposure.

    Time frame: From first dose of study treatment administration until end of treatment, assessed up to approximately 6 months

Secondary outcomes

  1. Overall Response Rate (ORR)

    Overall Response Rate (ORR) was defined as the proportion of subjects with a confirmed best overall response of complete response (CR) or partial response (PR), per RECIST v1.1 by investigator assessment. * Complete Response (CR) - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have a reduction in short axis to \< 10 mm (the sum could not be "0" if target nodes were present). * Partial Response (PR) - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose of study treatment through study completion (up to approximately 34 months)

  2. Overall Intracranial Response Rate (OIRR)

    Overall Intracranial Response Rate (OIRR) was calculated as the overall response rate (ORR; complete response \[CR\] plus partial response \[PR\]) of lesions in the brain among patients with measurable intracranial disease at baseline, per RECIST v1.1 by investigator assessment. * Complete Response (CR) - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have a reduction in short axis to \< 10 mm (the sum could not be "0" if target nodes were present). * Partial Response (PR) - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose of study treatment through study completion (up to approximately 34 months)

  3. Duration of Response (DOR)

    Duration of Response (DOR) was defined as the time from the first documented response (complete response \[CR\] or partial response \[PR\]) to the first documented disease progression or death, as assessed by the investigator per RECIST version 1.1. Patients who did not experience disease progression or death from any cause were censored at the date of the last adequate tumor assessment prior to the start of any new antineoplastic therapy. It should be noted that the response counts presented in this section are based on confirmed best overall response (BOR) per RECIST v1.1 criteria. In contrast, response counts used in time-to-event analyses (e.g., DOR and time to response \[TTR\]) may differ, as these analyses are based on observed CR or PR at any assessment timepoint derived from raw data.

    Time frame: From first documented response to disease progression or death, assessed through study completion (up to approximately 34 months)

  4. Time To Response (TTR)

    Time to Response (TTR) was defined as the time from the first dose of capmatinib to the first documented response of CR or PR, per RECIST v1.1 by investigator assessment.

    Time frame: From first dose of study treatment through first documented response, assessed through study completion (up to approximately 34 months)

  5. Disease Control Rate (DCR)

    Disease Control Rate (DCR) was defined as the proportion of patients with CR or PR or stable disease (SD), per RECIST v1.1 by investigator assessment. * Complete Response (CR) - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have a reduction in short axis to \< 10 mm (the sum could not be "0" if target nodes were present). * Partial Response (PR) - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. * Stable Disease (SD) - Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters recorded while on study.

    Time frame: From first dose of study treatment through study completion (up to approximately 34 months)

  6. Progression Free Survival (PFS)

    Progression-Free Survival (PFS) was defined as the time from the first dose of capmatinib to the first documented disease progression per RECIST v1.1 by investigator assessment or death from any cause. If a patient had not progressed or was not known to have died at the date of the analysis cut-off or had received any further anticancer therapy, PFS was censored at the date of the last adequate tumor evaluation before the cut-off date or before the start of the new anticancer therapy, whichever occurred earlier. PFS was censored at the last adequate tumor assessment if one of the following occurred: (1) absence of an event, (2) the event occurred after initiation of a new anticancer therapy, or (3) the event occurred after two or more missing tumor assessments.

    Time frame: From first dose of study treatment to first documented progression or death, assessed through study completion (up to approximately 34 months)

07

Results

Posted Oct 2, 2026

Participant flow

This study was conducted at 26 centers in India.

Participant flow — Overall Study
MilestoneCapmatinib
Started50
Full analysis set (fas)44
Completed27
Not completed23
Withdrew: Withdrawal by subject4
Withdrew: Adverse event1
Withdrew: Progressive disease13
Withdrew: Death5

Outcome measures

PrimaryPercentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events (Serious TEAEs)

Treatment-emergent adverse events (TEAEs) were adverse events that occurred or worsened following initiation of study treatment and up to 30 days after the last dose of the study drug. Serious treatment-emergent adverse events (serious TEAEs) were TEAEs that met the criteria for a serious adverse event, defined as any adverse event that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was an abnormal pregnancy outcome.

Time frame:
From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events (Serious TEAEs)
Percentage of participantsCapmatinib
At least one Treatment-emergent adverse events (TEAEs)88 (75.7 to 95.5)
At least one Serious treatment-emergent adverse events (serious TEAEs)28 (16.2 to 42.5)
PrimaryPercentage of Participants With Dose Modifications

Percentage of participants experiencing dose modifications, including dose interruptions and dose reductions. Dose modifications were implemented to manage intolerance to the protocol-specified regimen and were based on the worst preceding toxicity graded according to NCI-CTCAE v5.0. Capmatinib dose reductions followed predefined dose levels (400 mg BID → 300 mg BID → 200 mg BID), with a maximum of two consecutive reductions and no reductions below 200 mg BID. Treatment was discontinued if clinically significant toxicity recurred at the lowest dose despite maximal supportive measures, or if treatment interruption exceeded 21 consecutive days, unless continuation was approved by the Novartis Medical Lead or designee. Dose re-escalation was permitted once after at least one treatment cycle (3 weeks) at the reduced dose, provided no dose-modifying adverse event occurred.

Time frame:
From first dose of study treatment administration until end of treatment, assessed up to approximately 6 months
Reported as:
Count of participants · Participants
Percentage of Participants With Dose Modifications
ParticipantsCapmatinib
Percentage of Participants With Dose Modifications14
PrimaryDose Intensity

Dose intensity was defined as the ratio of actual cumulative dose received to the actual duration of exposure.

Time frame:
From first dose of study treatment administration until end of treatment, assessed up to approximately 6 months
Reported as:
Mean · mg/Day
Dose Intensity
mg/DayCapmatinib
Dose Intensity762.4481 ± 66.48123
SecondaryOverall Response Rate (ORR)

Overall Response Rate (ORR) was defined as the proportion of subjects with a confirmed best overall response of complete response (CR) or partial response (PR), per RECIST v1.1 by investigator assessment. * Complete Response (CR) - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have a reduction in short axis to \< 10 mm (the sum could not be "0" if target nodes were present). * Partial Response (PR) - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose of study treatment through study completion (up to approximately 34 months)
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsCapmatinib
Overall Response Rate (ORR)40.9 (26.3 to 56.8)
SecondaryOverall Intracranial Response Rate (OIRR)

Overall Intracranial Response Rate (OIRR) was calculated as the overall response rate (ORR; complete response \[CR\] plus partial response \[PR\]) of lesions in the brain among patients with measurable intracranial disease at baseline, per RECIST v1.1 by investigator assessment. * Complete Response (CR) - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have a reduction in short axis to \< 10 mm (the sum could not be "0" if target nodes were present). * Partial Response (PR) - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose of study treatment through study completion (up to approximately 34 months)
Reported as:
Count of participants · Participants
Overall Intracranial Response Rate (OIRR)
ParticipantsCapmatinib
Overall Intracranial Response Rate (OIRR) by RECIST 1.11
Overall Intracranial Response Rate (OIRR) by RECIST 1.1 for Treatment Naive Subjects1
Overall Intracranial Response Rate (OIRR) by RECIST 1.1 for Prior Treated Subjects0
SecondaryDuration of Response (DOR)

Duration of Response (DOR) was defined as the time from the first documented response (complete response \[CR\] or partial response \[PR\]) to the first documented disease progression or death, as assessed by the investigator per RECIST version 1.1. Patients who did not experience disease progression or death from any cause were censored at the date of the last adequate tumor assessment prior to the start of any new antineoplastic therapy. It should be noted that the response counts presented in this section are based on confirmed best overall response (BOR) per RECIST v1.1 criteria. In contrast, response counts used in time-to-event analyses (e.g., DOR and time to response \[TTR\]) may differ, as these analyses are based on observed CR or PR at any assessment timepoint derived from raw data.

Time frame:
From first documented response to disease progression or death, assessed through study completion (up to approximately 34 months)
Reported as:
Median · Months
Duration of Response (DOR)
MonthsCapmatinib
Duration of Response (DOR)5.35 (3.12 to NA)
SecondaryTime To Response (TTR)

Time to Response (TTR) was defined as the time from the first dose of capmatinib to the first documented response of CR or PR, per RECIST v1.1 by investigator assessment.

Time frame:
From first dose of study treatment through first documented response, assessed through study completion (up to approximately 34 months)
Reported as:
Median · Months
Time To Response (TTR)
MonthsCapmatinib
Time To Response (TTR)3.45 (1.51 to 8.38)
SecondaryDisease Control Rate (DCR)

Disease Control Rate (DCR) was defined as the proportion of patients with CR or PR or stable disease (SD), per RECIST v1.1 by investigator assessment. * Complete Response (CR) - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) were required to have a reduction in short axis to \< 10 mm (the sum could not be "0" if target nodes were present). * Partial Response (PR) - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. * Stable Disease (SD) - Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters recorded while on study.

Time frame:
From first dose of study treatment through study completion (up to approximately 34 months)
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsCapmatinib
Disease Control Rate (DCR)90.9 (78.3 to 97.5)
SecondaryProgression Free Survival (PFS)

Progression-Free Survival (PFS) was defined as the time from the first dose of capmatinib to the first documented disease progression per RECIST v1.1 by investigator assessment or death from any cause. If a patient had not progressed or was not known to have died at the date of the analysis cut-off or had received any further anticancer therapy, PFS was censored at the date of the last adequate tumor evaluation before the cut-off date or before the start of the new anticancer therapy, whichever occurred earlier. PFS was censored at the last adequate tumor assessment if one of the following occurred: (1) absence of an event, (2) the event occurred after initiation of a new anticancer therapy, or (3) the event occurred after two or more missing tumor assessments.

Time frame:
From first dose of study treatment to first documented progression or death, assessed through study completion (up to approximately 34 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsCapmatinib
Progression Free Survival (PFS)6.31 (4.60 to NA)

Adverse events

Collected over On-treatment Adverse Events (AEs) and deaths were collected from first dose of study medication until the last dose plus 30 days safety follow-up, assessed up to approximately 7 months.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Capmatinib7/50 (14%)14/50 (28%)42/50 (84%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventCapmatinib
Cardiac arrestCardiac disorders2/50
Sudden deathGeneral disorders and administration site conditions2/50
AnaemiaBlood and lymphatic system disorders1/50
Pericardial effusionCardiac disorders1/50
Small intestinal obstructionGastrointestinal disorders1/50
Non-cardiac chest painGeneral disorders and administration site conditions1/50
PyrexiaGeneral disorders and administration site conditions1/50
BronchitisInfections and infestations1/50
Lower respiratory tract infectionInfections and infestations1/50
SepsisInfections and infestations1/50
Most frequent other events
Showing 10 of 38
Most frequent other events
EventCapmatinib
Oedema peripheralGeneral disorders and administration site conditions22/50
VomitingGastrointestinal disorders13/50
FatigueGeneral disorders and administration site conditions10/50
HypoalbuminaemiaMetabolism and nutrition disorders10/50
HypocalcaemiaMetabolism and nutrition disorders10/50
DyspnoeaRespiratory, thoracic and mediastinal disorders9/50
NauseaGastrointestinal disorders8/50
DiarrhoeaGastrointestinal disorders7/50
PyrexiaGeneral disorders and administration site conditions7/50
CoughRespiratory, thoracic and mediastinal disorders7/50

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Capmatinib
Mean65.7 ± 8.96
Sex: Female, Male
Sex: Female, Male(Participants)Capmatinib
Female17
Male33
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Capmatinib
American Indian or Alaska Native0
Asian50
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

15 sites
  • Novartis Investigative Site
    Gujarat, Gujarat 380016, India
  • Novartis Investigative Site
    Mangalore, Karnataka 575002, India
  • Novartis Investigative Site
    Thalassery, Kerala 670103, India
  • Novartis Investigative Site
    Trivandrum, Kerala 695011, India
  • Novartis Investigative Site
    Bhopal, Madhya Pradesh 462001, India
  • Novartis Investigative Site
    Mumbai, Maharashtra 400012, India
  • Novartis Investigative Site
    Mumbai, Maharashtra 400056, India
  • Novartis Investigative Site
    Nagpur, Maharashtra 441108, India
  • Novartis Investigative Site
    Pune, Maharashtra 411040, India
  • Novartis Investigative Site
    New Delhi, National Capital Territory of Delhi 110029, India
  • Novartis Investigative Site
    Bhubaneswar, Odisha 751007, India
  • Novartis Investigative Site
    Hyderabad, Telangana 500004, India
  • Novartis Investigative Site
    Varanasi, Uttar Pradesh 221005, India
  • Novartis Investigative Site
    Kolkata, West Bengal 700020, India
  • Novartis Investigative Site
    Puducherry, 605006, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Aug 2025, 35 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 43 phase 4 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's 35 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2021
First posted
Nov 5, 2021
StartActual
Sep 3, 2022
Primary completionActual
Aug 4, 2025
CompletionActual
Aug 4, 2025
Results first posted
Oct 2, 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted, then revised
posted Oct 2, 2026 · revised Oct 26, 2026
Eligibility
9 inclusion criteria edited; 5 exclusion criteria edited, 1 added, 2 removed
What changed in the criteria
Inclusion criteria
  • EditedSigned informed consent form (ICF) must be obtained prior to participation in the study.
  • EditedStage IIIB/IIIC (not amenable to surgery, radiation or multi-modality therapy) or Stage IVMetastatic NSCLC (Stage IV, according to Version 8 of the AJCC Staging Manual) either treatment naivenaïve or progressed (clinically and/or radiologically) on 1 or more lines of systemic therapy at the time of study entry.
  • EditedHistologically or cytologically confirmed diagnosis of NSCLC with confirmed EGFR wild- type (EGFR Negative) and ALK rearrangement negative and who have tested positive test for MET exon14 skipping mutation (Locally available MET report either by reverse transcriptase polymerase chain reaction [RT-PCR] or Next Generation Sequencing [NGS] would be considered, in case not available, MET testing would be done through NGS based platform during molecular pre-screening done as part of the study).
  • EditedAt least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
  • EditedPatients must have adequate organ function, including the following laboratory values at the screening visit:
  • EditedTotal bilirubin ≤1.5 ULN (upper limit of normal (ULN) (except in patients with Gilbert's syndrome, who may be included if total bilirubin is ≤3.0 x ULN and direct bilirubin is ≤1.5 x ULN))
  • EditedAspartate transaminase (AST) ≤3 x ULN, except for patients with liver metastasis, who may only be included if AST ≤5 x ULN
  • EditedAlanine transaminase (ALT) ≤3 x ULN, except for patients with liver metastasis, who may only be included if ALT ≤5 x ULN
  • EditedAlkaline phosphatase (ALP) ≤5.0 x ULN
Exclusion criteria
  • EditedPrior treatment with any MET inhibitor or hepatocyte growth factor -targeting therapy.
  • EditedPatientsPatient with clinically significant heart diseases like unstable angina/acute myocardial infarctioninfraction within 6 months prior to screening, NYHA class III-IV congestive cardiac failure, uncontrolled hypertension, arrhythmias or QTcF ≥470 ms on the screening electrocardiogram (ECG).
  • RemovedThoracic radiotherapy to lung fields ≤4 weeks prior to starting capmatinib or patients who have not recovered from radiotherapy-related toxicities.
  • EditedThoracic radiotherapy to lung fields ≤4 weeks prior to starting Capmatinib or patients who have not recovered from radiotherapy-related toxicities. For all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy ≤2 weeks prior to starting capmatinibCapmatinib or patients who have not recovered from radiotherapy-related toxicities. Palliative radiotherapy for bone lesions ≤2 weeks prior to starting capmatinibCapmatinib is allowed.
  • RemovedPrevious (within 28 days) or concomitant participation in another clinical study with investigational medicinal product(s).
  • AddedPatients with prior systemic anti-cancer (chemotherapy, immunotherapy, biologic therapy, vaccine) and investigational agents within 4 weeks or ≤5 x half-life of the agent (whichever is shorter) before the first dose of Capmatinib. If previous treatment is a monoclonal antibody, then the treatment must be discontinued at least 4 weeks before first dose of Capmatinib. If previous treatment is an oral targeted agent, then the treatment must be discontinued at least 5 times the half-life of the agent.
  • EditedTotal abstinence (when this is in line with the preferred and usual lifestyle of the patient). Note that periodicPeriodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not considered highly effective and therefore not acceptable methods of contraception.
  • EditedUse of oral, (estrogen and progesterone), injected, or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking treatment.
Oct 2, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedPercentage of participants with Adverse Events (AEs)Participants With Dose ModificationsTime frame: From first dose of study treatment administration until end of study, assessed up to 7 months → From first dose of study treatment administration until end of treatment, assessed up to approximately 6 months
  • EditedDose intensityIntensityTime frame: From first dose of study treatment administration until end of treatment, assessed up to 6 months → From first dose of study treatment administration until end of treatment, assessed up to approximately 6 months
  • ChangedBefore Percentage of participants with dose modificationsNow Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events (Serious TEAEs)Time frame: From first dose of study treatment administration until end of treatment, assessed up to 6 months → From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months
Oct 2, 2026
Documents
Secondary outcomes
2 edited, 4 time frame changed, 4 description edited
What changed in the outcomes
  • EditedDuration of Response (DOR)Time frame: From first documented response to first documented progression or death, assessed up to 7 months → From first documented response to disease progression or death, assessed through study completion (up to approximately 34 months)
  • EditedTime To responseResponse (TTR)Time frame: From first dose of study treatment up to first documented response, assessed up to 7 months → From first dose of study treatment through first documented response, assessed through study completion (up to approximately 34 months)
  • Time frameOverall Response Rate (ORR)From first dose of study treatment up to a maximum duration of 7 months → From first dose of study treatment through study completion (up to approximately 34 months)
  • Time frameOverall Intracranial Response Rate (OIRR)From first dose of study treatment up to a maximum duration of 7 months → From first dose of study treatment through study completion (up to approximately 34 months)
  • Time frameDisease Control Rate (DCR)From first dose of study treatment up to a maximum duration of 7 months → From first dose of study treatment through study completion (up to approximately 34 months)
  • Time frameProgression Free Survival (PFS)From first dose of study treatment to first documented progression or death, assessed up to a maximum duration of 7 months → From first dose of study treatment to first documented progression or death, assessed through study completion (up to approximately 34 months)
  • DescriptionDisease Control Rate (DCR): how it is measured was reworded
  • DescriptionOverall Intracranial Response Rate (OIRR): how it is measured was reworded
  • DescriptionOverall Response Rate (ORR): how it is measured was reworded
  • DescriptionProgression Free Survival (PFS): how it is measured was reworded
Oct 2, 2026
Show all 2 updates
  1. Oct 26, 2026
    Posted results revised
    + 1 other change: references
  2. Oct 2, 2026
    Results posted
    Eligibility 9 inclusion criteria edited; 5 exclusion criteria edited, 1 added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • EditedSigned informed consent form (ICF) must be obtained prior to participation in the study.
    • EditedStage IIIB/IIIC (not amenable to surgery, radiation or multi-modality therapy) or Stage IVMetastatic NSCLC (Stage IV, according to Version 8 of the AJCC Staging Manual) either treatment naivenaïve or progressed (clinically and/or radiologically) on 1 or more lines of systemic therapy at the time of study entry.
    • EditedHistologically or cytologically confirmed diagnosis of NSCLC with confirmed EGFR wild- type (EGFR Negative) and ALK rearrangement negative and who have tested positive test for MET exon14 skipping mutation (Locally available MET report either by reverse transcriptase polymerase chain reaction [RT-PCR] or Next Generation Sequencing [NGS] would be considered, in case not available, MET testing would be done through NGS based platform during molecular pre-screening done as part of the study).
    • EditedAt least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
    • EditedPatients must have adequate organ function, including the following laboratory values at the screening visit:
    • EditedTotal bilirubin ≤1.5 ULN (upper limit of normal (ULN) (except in patients with Gilbert's syndrome, who may be included if total bilirubin is ≤3.0 x ULN and direct bilirubin is ≤1.5 x ULN))
    • EditedAspartate transaminase (AST) ≤3 x ULN, except for patients with liver metastasis, who may only be included if AST ≤5 x ULN
    • EditedAlanine transaminase (ALT) ≤3 x ULN, except for patients with liver metastasis, who may only be included if ALT ≤5 x ULN
    • EditedAlkaline phosphatase (ALP) ≤5.0 x ULN
    Exclusion criteria
    • EditedPrior treatment with any MET inhibitor or hepatocyte growth factor -targeting therapy.
    • EditedPatientsPatient with clinically significant heart diseases like unstable angina/acute myocardial infarctioninfraction within 6 months prior to screening, NYHA class III-IV congestive cardiac failure, uncontrolled hypertension, arrhythmias or QTcF ≥470 ms on the screening electrocardiogram (ECG).
    • RemovedThoracic radiotherapy to lung fields ≤4 weeks prior to starting capmatinib or patients who have not recovered from radiotherapy-related toxicities.
    • EditedThoracic radiotherapy to lung fields ≤4 weeks prior to starting Capmatinib or patients who have not recovered from radiotherapy-related toxicities. For all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy ≤2 weeks prior to starting capmatinibCapmatinib or patients who have not recovered from radiotherapy-related toxicities. Palliative radiotherapy for bone lesions ≤2 weeks prior to starting capmatinibCapmatinib is allowed.
    • RemovedPrevious (within 28 days) or concomitant participation in another clinical study with investigational medicinal product(s).
    • AddedPatients with prior systemic anti-cancer (chemotherapy, immunotherapy, biologic therapy, vaccine) and investigational agents within 4 weeks or ≤5 x half-life of the agent (whichever is shorter) before the first dose of Capmatinib. If previous treatment is a monoclonal antibody, then the treatment must be discontinued at least 4 weeks before first dose of Capmatinib. If previous treatment is an oral targeted agent, then the treatment must be discontinued at least 5 times the half-life of the agent.
    • EditedTotal abstinence (when this is in line with the preferred and usual lifestyle of the patient). Note that periodicPeriodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not considered highly effective and therefore not acceptable methods of contraception.
    • EditedUse of oral, (estrogen and progesterone), injected, or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking treatment.
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedPercentage of participants with Adverse Events (AEs)Participants With Dose ModificationsTime frame: From first dose of study treatment administration until end of study, assessed up to 7 months → From first dose of study treatment administration until end of treatment, assessed up to approximately 6 months
    • EditedDose intensityIntensityTime frame: From first dose of study treatment administration until end of treatment, assessed up to 6 months → From first dose of study treatment administration until end of treatment, assessed up to approximately 6 months
    • ChangedBefore Percentage of participants with dose modificationsNow Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events (Serious TEAEs)Time frame: From first dose of study treatment administration until end of treatment, assessed up to 6 months → From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months
    Secondary outcomes 2 edited, 4 time frame changed, 4 description edited
    What changed in the outcomes
    • EditedDuration of Response (DOR)Time frame: From first documented response to first documented progression or death, assessed up to 7 months → From first documented response to disease progression or death, assessed through study completion (up to approximately 34 months)
    • EditedTime To responseResponse (TTR)Time frame: From first dose of study treatment up to first documented response, assessed up to 7 months → From first dose of study treatment through first documented response, assessed through study completion (up to approximately 34 months)
    • Time frameOverall Response Rate (ORR)From first dose of study treatment up to a maximum duration of 7 months → From first dose of study treatment through study completion (up to approximately 34 months)
    • Time frameOverall Intracranial Response Rate (OIRR)From first dose of study treatment up to a maximum duration of 7 months → From first dose of study treatment through study completion (up to approximately 34 months)
    • Time frameDisease Control Rate (DCR)From first dose of study treatment up to a maximum duration of 7 months → From first dose of study treatment through study completion (up to approximately 34 months)
    • Time frameProgression Free Survival (PFS)From first dose of study treatment to first documented progression or death, assessed up to a maximum duration of 7 months → From first dose of study treatment to first documented progression or death, assessed through study completion (up to approximately 34 months)
    • DescriptionDisease Control Rate (DCR): how it is measured was reworded
    • DescriptionOverall Intracranial Response Rate (OIRR): how it is measured was reworded
    • DescriptionOverall Response Rate (ORR): how it is measured was reworded
    • DescriptionProgression Free Survival (PFS): how it is measured was reworded
    + 5 other changes: verification date, description, site details, index terms and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05110196
Responsible party
Sponsor
First posted
Nov 5, 2021
Start date
Sep 3, 2022
Primary completion
Aug 4, 2025
Completion
Aug 4, 2025
Results posted
Oct 2, 2026
Last update
Oct 26, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capmatinib

Start the discussion